The Ministry of Health and Prevention (MoHAP) and Abu Dhabi Health Services Company (SEHA) conducted a supplementary study, following which Abu Dhabi has announced that the Sinopharm vaccination has proven to lower Covid-19 infection rates, and minimize its effects on children between the age of 3 to 17 years old.

This study observed the effectiveness of the Sinopharm vaccine in reducing infection rates and intensity of the symptoms in the target population. Examination of nine hundred children was done throughout this study; these children met the criteria for partaking in the study. Investigators of the study took parents' consent, and all young volunteers are closely monitored and cared for at every step of the whole process. 

Every suitable medical protocol is achieved in regard to the highest international standard. As the measures will be put in place, preliminary studies will be announced to develop plans for students to return to school in a safe and healthy environment.

Dr Nawal Al Kaabi, Principal Investigator for Phase III Trials COVID-19 vaccine, disclosed that the registration for this study was successful because the required number of children for the research were recruited in a short period.

This study is unique as the United Arab Emirates is the first country in the Middle East and North Africa to conduct a vaccine effectiveness study with this age group as a target population. The investigators of this study expressed gratitude towards the research participants and their efforts to combat the COVID-19 pandemic.

SOURCE: Gulf News